Hepcidin, a liver-derived hormone, negatively regulates circulating iron levels through an increase in its expression in response to iron overload. Inflammation also increases production of hepcidin, potentially leading to inflammatory anemia. We previously revealed that proinflammatory cytokine interleukin (IL)-1β increased hepcidin expression through its transcriptional stimulation in hepatocytes. Induction of CCAAT-enhancer-binding protein (C/EBP) δ and IL-6 in response to IL-1β treatment stimulated hepcidin transcription via the C/EBP-binding site (C/EBP-BS) and signal transducer and activator of transcription (STAT)-BS on the hepcidin promoter, respectively. Here, we show an additional pathway responsible for IL-1β-induced hepcidin transcription. IL-1β stimulated phosphorylation of c-Jun N-terminal kinase (JNK) and its substrates c-Jun and JunB. SP600125, a JNK inhibitor, blocked IL-1β-induced phosphorylation of c-Jun and JunB as well as IL-1β-induced expression and transcription of hepcidin. Reporter assays for hepcidin transcription revealed that reporters with mutations of cAMP response element (CRE) site B, a putative Jun binding element, decreased responsiveness to IL-1β, and that activated JunB, but not c-Jun, conferred IL-1β-induced hepcidin transcription. Furthermore, binding of JunB to hepcidin promoter was increased by IL-1β. The present study indicated that IL-1β activates JNK and subsequently stimulates JunB activation, leading to hepcidin transcription via CRE site B on the hepcidin promoter. The present experiment provides novel insights into the molecular mechanisms underlying induction of hepcidin by inflammation and alteration of iron homeostasis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.cyto.2018.09.014 | DOI Listing |
Am J Hematol
January 2025
Keros Therapeutics, Lexington, Massachusetts, USA.
Patients with chronic inflammation are burdened with anemia of inflammation (AI), where inflammatory cytokines inhibit erythropoiesis, impede erythropoietin production, and limit iron availability by inducing the iron regulator hepcidin. High hepcidin hinders iron absorption and recycling, thereby worsening the impaired erythropoiesis by restricting iron availability. AI management is important as anemia impacts quality of life and potentially affects morbidity and mortality.
View Article and Find Full Text PDFAnemia of Inflammation is a prevalent co-morbidity in patients with chronic inflammatory disorders. Inflammation causes hypoferremia and iron-restricted erythropoiesis by limiting Ferroportin (FPN)-mediated iron export from macrophages that recycle senescent erythrocytes. Macrophage cell surface expression of FPN is reduced by hepcidin-induced degradation and/or by repression of FPN (Slc40a1) transcription via cytokine and Toll-like receptor (TLR) stimulation.
View Article and Find Full Text PDFHematology Am Soc Hematol Educ Program
December 2024
Medical and Research Service, Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN.
Anemia is a hallmark of chronic kidney disease (CKD), worsens with disease progression, and profoundly affects a patient's well-being. Major pathogenic factors are inadequate kidney erythropoietin (EPO) production and absolute and functional iron deficiency. The 2 mainstays of current anemia treatment are a) replacement therapy with recombinant EPO or 1 of its glycosylated derivatives, administered subcutaneously or intravenously, and b) intravenous (IV) iron injections.
View Article and Find Full Text PDFFront Cell Infect Microbiol
November 2024
Membrane Protein Structural Biology Group, Center for Structural Systems Biology (CSSB), Hamburg, Germany.
Host iron deficiency is protective against severe malaria as the human malaria parasite depends on bioavailable iron from its host to proliferate. The essential pathways of iron acquisition, storage, export, and detoxification in the parasite differ from those in humans, as orthologs of the mammalian transferrin receptor, ferritin, or ferroportin, and a functional heme oxygenase are absent in . Thus, the proteins involved in these processes may be excellent targets for therapeutic development, yet remain largely unknown.
View Article and Find Full Text PDFBlood
October 2024
Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!